Bioventus Inc.
BVS
$9.15
-$0.36-3.79%
| 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 573.28M | 555.06M | 536.89M | 522.74M | 512.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 573.28M | 555.06M | 536.89M | 522.74M | 512.35M |
| Cost of Revenue | 185.05M | 183.19M | 179.72M | 180.09M | 184.15M |
| Gross Profit | 388.23M | 371.87M | 357.17M | 342.65M | 328.19M |
| SG&A Expenses | 328.26M | 320.09M | 308.87M | 301.43M | 303.88M |
| Depreciation & Amortization | 7.65M | 7.99M | 8.24M | 8.47M | 8.84M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 534.61M | 524.92M | 509.69M | 502.26M | 510.32M |
| Operating Income | 38.68M | 30.14M | 27.20M | 20.49M | 2.03M |
| Income Before Tax | -49.13M | -57.76M | -61.12M | -26.02M | -121.11M |
| Income Tax Expenses | -5.29M | -6.59M | -6.58M | 1.14M | 85.00K |
| Earnings from Continuing Operations | -43.83 | -51.17 | -54.54 | -27.16 | -121.20 |
| Earnings from Discontinued Operations | -- | 0.00 | 0.00 | 0.00 | -59.49M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 10.29M | 11.69M | 12.58M | 5.51M | 24.46M |
| Net Income | -33.54M | -39.48M | -41.96M | -21.65M | -156.23M |
| EBIT | 38.68M | 30.14M | 27.20M | 20.49M | 2.03M |
| EBITDA | 80.61M | 74.00M | 72.61M | 67.40M | 53.63M |
| EPS Basic | -0.52 | -0.62 | -0.66 | -0.34 | -2.51 |
| Normalized Basic EPS | 0.17 | 0.10 | 0.06 | -0.12 | 0.00 |
| EPS Diluted | -0.52 | -0.62 | -0.66 | -0.34 | -2.51 |
| Normalized Diluted EPS | 0.17 | 0.10 | 0.06 | -0.12 | 0.00 |
| Average Basic Shares Outstanding | 258.15M | 255.80M | 253.36M | 251.86M | 250.60M |
| Average Diluted Shares Outstanding | 258.15M | 255.80M | 253.36M | 251.86M | 250.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
